Full history for every metric is available with a Kvantra account
Redx Pharma Plc (REDX.L)
Key financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 3 | 6 | 10 | 19 | 4 | 4 |
| Operating profit | £m | -34 | -33 | |||||
| Net profit | £m | -9 | -4 | -9 | -22 | -18 | -33 | -33 |
| EPS reported | £ | -0.10 | -0.10 | |||||
| Operating cashflow per share | £ | -0.10 | -0.10 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | -0.10 | -0.10 | |||||
| Free cash flow | £m | -35 | -35 | |||||
| Net debt | £m | -0 | -2 | |||||
| Book value equity | £m | 3 | 3 | |||||
| Book value per share | £ | 0.01 | 0.01 | |||||
| Number of shares | m | 334.91 | 334.91 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 25.95 | 17.39 | |||||
| P/S LTM | x | 20.72 | 13.89 | |||||
| P/FCF LTM | x | -2.49 | -1.67 | |||||
| EV/EBITDA LTM | x | -2.89 | -1.86 | |||||
| EV/Sales LTM | x | 20.62 | 13.32 | |||||
| Earnings Yield LTM | % | -38.08% | -66.00% | |||||
| FCF Yield | % | -40.13% | -59.89% | |||||
| Quality | ||||||||
| ROE | % | -988.26% | -180.80% | |||||
| ROIC | % | -160.77% | -160.77% | |||||
| Operating margin | % | -804.85% | -804.85% | |||||
| Gross margin | % | 77.15% | 77.15% | |||||
| FCF/Sales | % | -831.56% | -831.56% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -77.52% | -77.52% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.98 | -1.98 | |||||
| Net Debt/EBITDA | x | 0.01 | 0.01 | |||||
| EBIT/Net interest | x | -18.78 | -18.78 | |||||
| Net debt/market cap | % | -0.47% | -4.05% | |||||
| Net debt/Equity | x | -0.12 | -0.70 | |||||
| Gross debt/equity | x | 5.27 | 5.27 | |||||
Company overview
Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in Macclesfield, concentrates its efforts on the discovery, early-stage preclinical development, and licensing of innovative small molecule drugs. The company primarily targets significant unmet medical needs in the therapeutic areas of oncology and fibrosis. Within its oncology portfolio, Redx is progressing RXC004, a porcupine inhibitor currently undergoing Phase II clinical evaluation for treating cancers driven by Wnt-ligands. Additionally, it maintains a research collaboration with Jazz Pharmaceuticals plc, aiming to identify and advance new drug candidates for two specific cancer pathways: the Ras/Raf/MAP kinase pathway. For fibrotic conditions, Redx Pharma is developing several compounds, including RXC007, an oral selective ROCK2 inhibitor intended for the treatment of various fibrotic diseases. Its pipeline also features a gastrointestinal-targeted ROCK inhibitor specifically designed to address fibrosis associated with Crohn's disease, along with a discoidin domain receptors (DDRs) inhibitor for a range of fibrotic disorders. Furthermore, the company is developing RXC006, another porcupine inhibitor, focused on combating fibrotic illnesses such as idiopathic pulmonary fibrosis.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Redx Pharma Plc (REDX.L)
Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in Macclesfield, concentrates its efforts on the discovery, early-stage preclinical development, and licensing of innovative small molecule drugs. The company primarily targets significant unmet medical needs in the therapeutic areas of oncology and fibrosis. Within its oncology portfolio, Redx is progressing RXC004, a porcupine inhibitor currently undergoing Phase II clinical evaluation for treating cancers driven by Wnt-ligands. Additionally, it maintains a research collaboration with Jazz Pharmaceuticals plc, aiming to identify and advance new drug candidates for two specific cancer pathways: the Ras/Raf/MAP kinase pathway. For fibrotic conditions, Redx Pharma is developing several compounds, including RXC007, an oral selective ROCK2 inhibitor intended for the treatment of various fibrotic diseases. Its pipeline also features a gastrointestinal-targeted ROCK inhibitor specifically designed to address fibrosis associated with Crohn's disease, along with a discoidin domain receptors (DDRs) inhibitor for a range of fibrotic disorders. Furthermore, the company is developing RXC006, another porcupine inhibitor, focused on combating fibrotic illnesses such as idiopathic pulmonary fibrosis.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free